Among infection‐related safety outcomes, UTI incidence was reported in 10 studies, with a significantly lower incidence in the SGLT2 inhibitor group compared with the control group (OR: 0.45 and 95% CI: 0.22–0.92) (Figure 2a), whereas the incidence of genital mycotic infection did not differ significantly between groups (Figure 2b). This evidence concerns the gene SLC5A2 and infection.